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Abstract 
The anti-inflammatory agent curcumin can selectively eliminate malignant rather than normal cells. 
The present study examined the effects of curcumin on the Lewis lung carcinoma (LLC) cell line 
and characterized a subpopulation surviving curcumin treatments. Cell density was measured after 
curcumin was applied at concentrations between 10 and 60 μM for 30 hours. Because of the high 
cell loss at 60 μM, this dose was chosen to select for surviving cells that were then used to establish 
a new cell line. The resulting line had approximately 20% slower growth than the original LLC cell 
line and based on ELISA contained less of two markers, NF-κB and ALDH1A, used to identify more 
aggressive cancer cells. We also injected cells from the original and surviving lines subcutaneously 
into syngeneic C57BL/6 mice and monitored tumor development over three weeks and found that 
the curcumin surviving-line remained tumorigenic. Because curcumin has been reported to kill 
cancer cells more effectively when administered with light, we examined this as a possible way of 
enhancing the efficacy of curcumin against LLC cells. When LLC cells were exposed to curcumin 
and light from a fluorescent lamp source, cell loss caused by 20 μM curcumin was enhanced by 
about 50%, supporting a therapeutic use of curcumin in combination with white light. This study is 
the first to characterize a curcumin-surviving subpopulation among lung cancer cells. It shows that 
curcumin at a high concentration either selects for an intrinsically less aggressive cell subpopulation 
or generates these cells. The findings further support a role for curcumin as an adjunct to tradi-
tional chemical or radiation therapy of lung and other cancers. 
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Introduction 
Curcumin,  a  yellow-orange  dye  in  the  spice 
turmeric, causes selective  apoptosis in many cancer 
cell  types  including  those  of  small-cell  lung  cancer 
while sparing normal cells (1-4). The therapeutic ef-
fects of curcumin against carcinogensis and progres-
sion  of  tumor  growth  depend  on  its  inhibition  of 
multiple intracellular signaling molecules, most nota-
bly  NF-κB  that  plays  a  central  role  in  various  re-
sponses leading to host defense and also inflamma-
tion (5-7). Curcumin has been documented in the In-
dian  medical  system  Ayurveda  for  over  6000  years 
and is still prominent in the diets of Asian countries 
(8).  Although  orally  administered  curcumin  is  re-
markably well tolerated and has been evaluated as a 
supplemental  chemotherapeutic  drug,  its  bioavaila-
bility is very poor. Oral administration of curcumin 
has shown no effect on mammary, liver, kidney (9) or 
lung cancers (10). Improvements in bioavailability are 
needed to increase the effectiveness of this promising 
drug, particularly for targets outside the gastrointes-
tinal tract. Alternative therapeutic approaches are to 
administer  curcumin  either  directly  to  tumors  or 
through  the  circulatory  system  either  alone  or  in 
combination with more traditional cancer treatments. 
When administered with radiation (11-16) or chemo-
therapy (17-20) curcumin sensitizes the tumor to the 
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treatment and improves outcome (21, 22).  
Many  cancers  return  following  chemotherapy 
because of resistant cells. In some cases, resistance has 
been attributed to cancer stem cells (CSCs), a small 
subpopulation of self-renewing cells that are thought 
to  be  critical  for  tumor  recurrence  and  progression 
and that can proliferate after chemotherapy and radi-
ation therapy (23, 24). In light of the potential benefits 
of curcumin delivered in combination with standard 
cancer therapies, it will be important to characterize 
cells  showing  tolerance  to  curcumin.  A  few  reports 
have identified the properties of curcumin-surviving 
subpopulations of tumors or cancer cell lines (25-28). 
Any examination of curcumin-resistance should con-
sider the possible presence of CSCs. 
In this study, we investigated the effect of cur-
cumin on the Lewis lung carcinoma (LLC) cell line. 
The  LLC  line  is  a  well-established  mouse  cancer 
model that is commonly used as a transplantable ma-
lignancy model in syngeneic C57BL/6 mice. We also 
generated  and  characterized  a  curcumin-surviving 
LLC sub-population and tested its ability to form tu-
mors in mice. Finally, we used LLC cells to replicate a 
reported synergistic effect of light and curcumin on 
cancer cells as a possible way of increasing the effi-
cacy of curcumin.  
Materials and Methods 
Animals 
A transgenic mPer1::luc mouse line that we used 
previously to produce LLC tumors (29) was bred and 
maintained in the BGSU Animal Care Facility under 
standard conditions of 12 hr light:12 hr dark and fed a 
reduced-fat mouse chow ad libitum. The mice were 
originally produced by Dr. Hajime Tei of Mitsubishi 
Kagaku Institute of Life Sciences, Tokyo through oo-
cyte  injection  and  were  on  a  C57BL/6  background 
(30). Although not utilized in this study, these mice 
contain the firefly luciferase gene luc controlled by the 
promoter  of  the  mPer1  gene,  enabling  biolumines-
cence  imaging  of  tumor  growth  (29).  The  mice  re-
ceived  humane  care  in  accordance  with  the  BGSU 
Institutional  Animal  Care  and  Use  Committee 
(IACUC). 
Lewis Lung Carcinoma (LLC) cell line 
The LLC cell line was provided by Dr. Stephen 
Kennel of the University of Tennessee Medical Center, 
Knoxville, TN. The cells were cultured in Dulbecco’s 
modified eagle medium (DMEM, GIBCO, Invitrogen, 
NY),  supplemented  with  penicillin  (100  U/ml), 
streptomycin (100 µg/ml) and 5 or 10% fetal bovine 
serum  (FBS,  Atlanta  Biological,  Lawrenceville,  GA), 
referred  to  here  as  complete  DMEM.  The  cultured 
cells  were  kept  in  100-mm  tissue  culture  dishes  at 
37°C in a humidified atmosphere containing 5% CO2 
(31). 
Curcumin treatment 
To determine the dose-dependent effect of cur-
cumin on LLC cells, the cultured cells were washed, 
trypsinized, collected, counted using a hemocytome-
ter (Hausser Scientific, PA) and subsequently plated 
in 24-well plates at a density of 5×104 cells/well and 
incubated at 37°C. Curcumin (purity 70%, Sigma) was 
dissolved in DMSO, and diluted in complete DMEM 
to provide a curcumin concentration ranging from 10 
to 60 μM. Twenty-four hours after plating, each of the 
four-well columns was washed with PBS once, and 
each column was exposed to 10, 20, 40 or 60 μM cur-
cumin. Four wells treated with complete DMEM or 
complete DMEM with 0.2% DMSO served as controls. 
After  incubation,  the  cell  density  was  assayed  with 
the  crystal  violet  staining  method  according  to  a 
standard  protocol  (32).  The  resulting  absorbance  of 
the  stained  cells  was  analyzed  with  ANOVA 
(OriginLab, Northampton, MA). The experiment was 
repeated with 2, 4, 8, 16, 24, or 30 hrs of curcumin 
exposure using a range of curcumin dosages. 
Curcumin-surviving LLC sub-population 
To select for a curcumin-surviving cell subpop-
ulation, LLC cells were plated into three 100-mm cell 
culture plates (106 cells/plate) containing 10 ml com-
plete DMEM and incubated at 37°C. After 24 hours, 
the  medium  was  removed  and  the  cells  were  incu-
bated in complete DMEM containing 60 μM curcumin 
dissolved in 0.2% DMSO for 30 hrs. After incubation, 
the curcumin-containing medium was removed and 
replaced  with  complete  DMEM  to  allow  cells  that 
survived the treatment to grow. After the surviving 
cells  formed  colonies  (normally  four  weeks  after 
treatment), they were passaged three times. The cell 
line  that  developed  was  designated  the  curcu-
min-surviving LLC line. 
Growth Curve 
To determine the rate of growth of both cell lines, 
cultured  cells  were  trypsinized,  collected,  counted 
and plated in 100-mm culture plates at a density of 106 
cells/plate. The cells were trypsinized, collected, and 
counted at 16, 24, 48, 72 and 96 hours after plating. For 
statistical analysis, three plates of cells were used at 
each time point.  
Enzyme-Linked Immunosorbent Assay 
(ELISA) 
ELISA  was  performed  as  described  previously  Journal of Cancer 2012, 3 
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(31).  Briefly,  the  original  LLC  line  and  the  curcu-
min-surviving  line  were  washed  with  PBS,  tryp-
sinized,  collected,  counted,  and  plated  into  96-well 
plates (5×104 cells/well). After incubation at 37°C for 
24 hrs, the plates were washed with PBS once and the 
cells were fixed with methanol for 10 minutes. The 
plates  were  then  washed  with  PBS  twice  and  incu-
bated with 100 μl complete DMEM containing rabbit 
polyclonal antibodies (anti-p65, Santa Cruz Biotech-
nology, SC-109, 200 µg/ml and anti-ALDH1A1, Pro-
teintech Group, 15910-1-AP, 133 µg/ml) at 37°C for 
two hours. The antibodies were tested at a range of 
dilutions (1:50, 1:100, 1:200, 1:400). Three replicates of 
each dilution were used for statistical analysis. One 
well with only cells was used as blank for each plate. 
After two hours of incubation at 37°C, the wells were 
washed three times with PBS to remove any unbound 
primary  antibody  and  incubated  with  100  μl 
β-galactosidase-conjugated goat anti-rabbit secondary 
antibody (1:500 dilution in complete DMEM) at 37°C 
for another two hrs. After incubation, the wells were 
washed with PBS three times and the cells were in-
cubated  with  100  μl  substrate  solution  (1  mg/ml 
P-nitrophenyl  β-D-galactopyranoside  in  phosphate 
buffer, pH 8.0) at 37°C for one hour in darkness. The 
development  of  a  yellow  color  indicated  a  positive 
reaction. The intensity of the color was measured with 
a MR-600 microwell plate reader (Dynatech Lab. Inc.) 
at 410 nm wavelength. The resulting absorbance was 
analyzed using ANOVA. 
Tumor injection and histology 
The  upper  rear  leg  of  the  mice  was  injected 
subcutaneously  with  106  LLC  cells  diluted  in  PBS. 
Three weeks after the injection, tumors were excised 
from euthanized mice, fixed in Histochoice (Amresco, 
Solon, OH) and embedded in paraffin at 57°C. Sec-
tions (5 to 10-μm thick) were mounted on glass slides, 
dewaxed, rehydrated through a series of ethanol di-
lutions and stained with hematoxylin and eosin for 
histological analysis. 
Curcumin and light treatment 
To investigate the effect of curcumin in combi-
nation with visible light, we plated the LLC cells in 
24-well plates at a density of 5×104 cells/well. After 24 
hours of incubation at 37°C, the cells were exposed to 
10, 20, 40 or 60 μM curcumin. After one-hour incuba-
tion, the cells were irradiated for 5 minutes with flu-
orescent light with an intensity of 120 μEinsteins m-2 
s-1  (measured  with  Apogee  Instrument’s  Quantum 
Meter).  The  light  source  was  a  portable  fluorescent 
light table containing one 13-watt tube directing light 
upwards through a white plastic diffuser, which was 
placed below two cool white F20T12 fluorescent bulbs 
(1200 lumens, Eco Lux Technology) positioned 90 mm 
above  the  light  table.  Each  cell  culture  plate  was 
placed at the center of the light table and irradiated 
simultaneously from above and below. While the ex-
perimental plates were exposed to light, the control 
plates  (treated  with  curcumin  but  not  exposed  to 
light) were removed from the incubator and kept in 
darkness  under  the  same  conditions  as  the  experi-
mental group (at room temperature and in room air). 
After the light treatment, all the plates were returned 
to the 37°C incubator and remained in the curcumin 
medium  for  a  total  of  24 hours  exposure.  The  cells 
were then stained with crystal violet and the cell den-
sity was analyzed as described above.  
Results 
The Effect of Curcumin on LLC Cells 
The dose-dependent effect of curcumin on LLC 
cells over a range of exposure times is shown in Fig-
ure 1A. The 2-hr curcumin exposure had a significant 
effect  only  at  60  μM,  whereas  the  8-hr  and  16-hr 
treatments were able to cause significant reduction of 
cells  given  the  lower  concentrations.  The  effect  of 
24-hr exposure was significant at 20-60 μM, and was 
similar to that at 30-hr exposure. The cell density of 
the curcumin-free control plate almost doubled dur-
ing the 30-hr period, while the higher curcumin dos-
ages  caused  a  decline  (Fig.  1A).  Cells  treated  with 
DMSO  were  not  significantly  different  from  cells 
given  complete  medium  alone.  Cell  viability  after 
treating LLC cells with 5, 10, 20, and 40 µM curcumin 
for 24 hrs was also evaluated using the MTT assay 
(data not shown). A significant 50% reduction in cell 
staining occurred between 20 and 40 µM (ANOVA, 
F=5.646, p=0.00129). 
Comparing the Curcumin-Surviving and 
Original LLC Cell Lines 
According to the dose-response curves, we chose 
a  30-hr  exposure  with  60  μM  curcumin  to  select  a 
curcumin-surviving  sub-population.  To  assess  the 
difference between the curcumin-surviving and orig-
inal  LLC  lines,  we  compared  growth  rate  and  re-
sponses to curcumin along with expression of NF-κB 
and ALDH1A1, both of which are markers associated 
with aggressive cancer cells such as CSCs. We treated 
the LLC line and the curcumin-surviving line with the 
same curcumin concentrations to establish a second 
set  of  dose-response  curves  (Fig.  1B).  The  curcu-
min-surviving line was slightly less sensitive to cur-
cumin than the original line.  Journal of Cancer 2012, 3 
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Figure 1. Reduction of LLC cell proliferation in response to curcumin exposure. A. Shown is the loss of cells caused by 
varying the curcumin (0-60 µM) and treatment interval (2-30 hrs). Each line represents the effect of one dosage of curcumin 
and each point is the mean absorbance in a crystal violet assay from four wells ± SD. B. Reduction of curcumin-surviving LLC 
cells in response to a second exposure of curcumin (0-60 µM for 30 hrs) compared with the original LLC cell line treated for 
30 hrs. Percent cell loss is the percent decline in absorbance relative to the DMSO control. Each point is mean absorbance 
of four wells ± SD. C. The growth rate of curcumin-surviving and original LLC lines. Cell counts were made at 16, 24, 48, 72 
and 96 hrs after plating. Each point is the mean of the number of cells in three plates ± SD. 
 
Growth  rate  measurements  showed  that  the 
curcumin-surviving  line  had  an  approximately  20% 
slower growth rate than the untreated LLC line (Fig. 
1C). After 96 hrs of culture, the original LLC line had 
approximately  50%  more  cells  than  the  curcu-
min-surviving line (Fig. 1C). ELISA was performed on 
both lines to determine the expression of NF-κB and 
ALDH1A1.  The  curcumin-surviving  line  showed  a 
lower  amount  of  ALDH1A1  and  NF-κB  than  the 
original line (Table 1, T-test, p<0.05, using 1:100 anti-
body dilution).  
 
 
Table 1. Evaluation of cancer stem cell markers by ELISA 
Primary 
Antibody 
Dilution 
NF-κB level  ALDH1A1 level 
Original 
LLC line 
Curcumin 
treated LLC 
line 
Original 
LLC line 
Curcumin 
treated LLC 
line 
1:100  1.233 ±0.10  1.000 ±0.10  0.354 ±0.006  0.108 ±0.001 
1:200  0.664 ±0.05  0.383 ±0.04  0.123 ±0.04  0.056 ±0.10 
1:400  0.294 ±0.08  0.066 ±0.01  0.0985 ±0.02  0.047 ±0.02 
Shown is the average optical density of three wells at 410 nm ±SD. 
 
 
Comparison of Curcumin-Surviving Line and 
the Original LLC Cell Line in vivo 
Mice that were of the same genetic background 
as  the  LLC  cells  were  used  to  compare  the  tumor-
igenicity  of  the  original  LLC  line  and  the  curcu-
min-treated cell line. Three mice were injected in the 
upper  right  leg  with  106  cells  from  the  curcu-
min-surviving line at the third passage after treating 
LLC  cells  with  curcumin.  Three  weeks  later,  each 
mouse  had  developed  small  tumors  that  were  then 
removed  by  dissection.  There  was  no  evidence  of 
metastasis  in  lung,  spleen,  liver,  intestine,  heart  or 
other  tissues  examined.  Histological  sections  made 
from the tumors revealed cell types found previously 
in tumors made from the original line (29). For exam-
ple, a compact central area of cancer cells and infil-
trating  stromal  cells,  as  described  previously,  were 
also  present  in  tumors  from  the  surviving-cell  line 
(Fig. 2). The only obvious difference was that tumors 
of  the  surviving  cell  line  appeared  to  contain  more 
closely spaced blood vessels passing through the mass 
of cancer cells (Figure 2A). 
In a second experiment, three mice were injected 
with the surviving line and three were injected with 
the original line. Tumors formed in all mice of both 
groups and, as in the first experiment, there was no 
evidence of metastasis at the macroscopic level. Fur-
thermore,  the  tumors  from  the  curcumin-surviving 
line appeared to be more heavily vascularized than 
tumors from the original line (Figure 2C). 
The Effect of Curcumin and Light on LLC cells 
It has been shown that curcumin in combination 
with  light  inhibits  the  growth  of  E. coli (33),  trans-
formed skin keratinocytes (34) and A-431 tumors in a 
xenograft  mouse  model  (35),  thereby  providing  a 
possible way to increase the effectiveness of curcumin 
by  combining  it  with  photodynamic  therapy  of  tu-
mors. We tested whether this effect can also be de-
tected with the LLC cell line. We evaluated whether  Journal of Cancer 2012, 3 
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possible  phototoxicity  or  light-absorption  by  the 
phenol red of normal cell culture media influences the 
combined  curcumin-light  effect.  LCC  cells  were 
maintained in phenol red containing medium (com-
plete DMEM) and non-phenol red complete medium. 
Above 10 µM the curcumin treatments in combination 
with light produced a greater cell loss than curcumin 
alone  in  cells  maintained  in  complete  DMEM  (Fig. 
3A). Above this same dosage cucumin also reduced 
the LLC cell cultures maintained in phenol red-free 
medium more effectively when combined with light 
exposure (Fig. 3B). 
Light  itself  also  produced  a  loss  of  cells  when 
delivered  without  curcumin  to  LLC  cells  in  either 
medium. This effect was larger in the phenol red-free 
medium (39.23%) than in complete DMEM (19.78%), 
as shown in Fig. 3A, B. When these results were plot-
ted as the percentage of the absorbance in the curcu-
min-free group (Fig. 3C, D), treatments above 10 µM 
produced a substantial effect in the complete medium 
and only a modest effect in the phenol red-free me-
dium. 
 
 
Figure 2. Sections through tumors formed from the cur-
cumin-surviving LLC cell line. A. Shown are LLC cells, with 
blue nuclei, near the boundary of the tumor where it is 
infiltrated  with  blood  cells  (small  arrow)  and  numerous 
blood vessels (large arrow). B. Sections also showed infil-
tration of muscle cells into the tumor (arrow). C. A rep-
resentative section from a tumor made from the original 
LLC cell line. The sections were stained with hematoxylin 
and eosin, and the scale bar equals 50 µm. 
 
Discussion 
Among all cancers, lung cancer is considered one 
of  the  deadliest  because  of  aggressive  tumor  cell 
growth and lack of adequate therapies. We selected a 
well studied lung cancer cell line to evaluate the use of 
curcumin at concentrations that are known to be cy-
totoxic to many different cancer cells (36). Previously, 
when  LLC  cells  were  used  in  an  orthotopic  tumor 
model, with the cells implanted in the lungs, curcu-
min  administered  orally  had  no  effect  on  tumor 
growth but did minimize metastasis to lymph nodes 
near the lungs (37), suggesting that curcumin or its 
metabolites  had  some  effects  despite  low  bioavaila-
bility following ingestion. 
We determined how LLC cells in vitro respond to 
a  range  of  curcumin  dosages  applied  for  different 
durations.  It  was  found  that  24  to  30-hr  treatments 
reduced  the  number  of  cells  in  a  dose-dependent 
manner, which is in agreement with published results 
using other cell lines (1) as well as LLC (37). However, 
a shorter treatment interval (2 or 4 hrs) significantly 
reduced  the  density  of  cells  only  when  they  were 
treated with the highest curcumin dose (60 µM).   Journal of Cancer 2012, 3 
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Figure 3. Effect of curcumin and visible light on LLC cell survival. LLC cells were pre-incubated with 0-40 μM curcumin for 
one hour and then either irradiated with visible light for 5 min or light protected (dark control). Curcumin was applied for 
a total of 30 hrs. A. Average absorbance following the crystal violet assay. B. Cells were treated as in A but were maintained 
in phenol red-free medium. C & D. Same absorbance data as in A & B replotted as percent of the zero-curcumin result. Each 
point is the mean of four wells ± SD. 
 
 
Because curcumin can alter a variety of molecu-
lar targets within cancer cells, we speculated that the 
cells  that  survived  the  treatment  might  be  either  a 
subset  of  the  cell  line  that  had  greater  intrinsic  re-
sistance to curcumin or LLC cells that had survived 
because  they  were  modified  by  curcumin  before  it 
could exert its lethal effects. Curcumin affects cellular 
pathways that rely on AP-1, HIF-1, AKT, NF-κB, and 
other cell signals (3, 6, 38-45). It has been argued that 
the elevated NFkB activity commonly found in more 
aggressive  cancer  cells  endows  them  with  an-
ti-apoptotic properties but also makes them particu-
larly vulnerable to negative selection by curcumin (5, 
46-48). Any cell alteration that would explain curcu-
min effects in this study would need to be transmis-
sible to daughter cells by either genetic or epigenetic 
changes. 
A third possibility is that the surviving cells were 
not  different  from  other  cells  and  merely  escaped 
curcumin by chance. To determine the characteristics 
of  the  surviving  subpopulation,  we  compared  the 
growth  rate,  tumorigenicity,  and  the  NF-κB  and 
ALDH1A1  expression  levels  of  both  lines.  The  sur-
viving  population  showed  a  lower  level  in  each  of 
these categories, suggesting that there was either se-
lection for a less aggressive line or generation of such 
a line by the curcumin treatment, what we are refer-
ring to as modification. Because the surviving cell line 
was found to be different from the original line, the 
third possibility, which does not infer special charac-
teristics of the survivors, can be rejected.  
Similarly,  the  curcumin  exposure  that  was  ap-
plied to the curcumin-surviving cell line revealed a 
slightly lower sensitivity to curcumin relative to the 
original line, indicating that the procedure may have 
selected  for  a  more  resistant  subpopulation  from 
within  the  original  line  or,  instead,  altered  a  small 
number of cells during the treatment thereby allowing  Journal of Cancer 2012, 3 
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them to survive. The LD50 for curcumin was increased 
by  about  50%.  This  result  has  implications  for  any 
cancer  therapy  in  which  cucumin  is  used  as  a 
chemotherapeutic  agent  against  cancer  cells,  rather 
than merely as a dietary supplement intended to serve 
as a cancer preventative. Instead of the typical out-
come  observed  with  other  chemotherapeutics,  cur-
cumin does not appear to leave behind more aggres-
sive  and  curcumin-resistant  tumor  cells  that  could 
lead to cancer recurrence. 
The outcome of the tumor growth experiment is 
consistent with the apparently slower growth of the 
curcumin-surviving cells in vitro relative to the origi-
nal LLC cells. These cells remained tumorigenic but 
did so less effectively, perhaps because of their slower 
growth rate. Although LLC cells may be representa-
tive of other cancer cell types, these results should be 
confirmed  by  examining  the  curcumin-surviving 
progeny  of  cancer  cells  derived  from  distinctly  dif-
ferent tissues.  
The results of these experiments are consistent 
with recent reports that indicate a loss of CSCs from 
cancer  cell  lines  in  response  to  a  single  curcumin 
treatment (49-51). According to the CSC theory, tumor 
recurrence and metastasis are primarily caused by a 
small  subpopulation  of  self-renewing  cells  that  can 
differentiate into other cancer cells. CSCs are consid-
ered  to  be  aggressive  and  more  resistant  cells  that 
escape from chemotherapy. In contrast, the surviving 
LLC cells had slower replication, slightly greater re-
sistance to curcumin, and lower levels of ALDH1A1 
and  NF-κB,  which  are  considered  markers  of  CSCs 
(52-54) and found in more robust cancer cells (55, 56). 
Although we have no direct evidence of CSCs in the 
LLC cell line, the explanation above does agree with 
the results and should be explored further by search-
ing for additional characteristics of CSCs in the cell 
cultures and LLC tumors. 
Studies suggest that direct interactions between 
CSCs  and  curcumin  are  credible  (25).  For  example, 
resistance  to  curcumin  in  melanoma  cells  has  been 
attributed  to  high  expression  of  the  ATP-binding 
cassette transporter ABCA1 leading to efflux of cur-
cumin from the cells (57). ABC transporters may pro-
vide CSCs with multidrug resistance that allows them 
to  survive  chemotherapy  (58).  Exclusion  of  fluores-
cent dyes by the elevated activity of ABC transporters 
can be used to identify putative CSCs and non-cancer 
stem cells (24, 59) and should be applied to LLC cells. 
One study does, however, suggest that the LLC 
line  lacks  a  distinct  CSC  subpopulation  and  argues 
instead that nearly all of the cells are tumorigenic (60). 
Nevertheless,  the  specific  proportion  of  CSC  cells 
found in cancer cell lines is apparently quite variable 
between lines and somewhat plastic within lines as it 
changes with factors in the media that have yet to be 
fully characterized (61). Results of the present study 
seem  to  be  best  explained  by  curcumin  either  pro-
ducing a sustained suppression of the CSC subpopu-
lation or tempering the aggressive tumorigenicity and 
growth that is perhaps characteristic of all cells within 
the  LLC  line.  In  either  case,  curcurmin  may  have 
caused an increased differentiation of the cells away 
from  the  normal  LLC  phenotype  as  has  been  de-
scribed for its effects on stem cells (51). 
We favor an explanation in which CSC proper-
ties are diminished by curcumin because this clarifies 
why  the  curcumin-surviving  cell  line  appears  less 
tumorigenic, and less sensitive to curcumin, and also 
expresses less of the markers of aggressive cells that 
are also attributes of CSCs. CSCs are hypothesized to 
divide slowly in tumors, thereby providing one ex-
planation  for  how  they  escape  the  effects  of  an-
ti-mitotic  chemotherapy  (62),  but  it  is  not  clear 
whether  they  divide  faster  in  vitro  than  non-CSCs. 
One interpretation of the slower growth of the cur-
cumin-surviving line is that it contains fewer aggres-
sively dividing cells which may or may not be CSCs. If 
curcumin is acting on CSCs within the LLC line, then 
this explanation requires that curcumin acts unlike the 
many  other chemicals that are toxic to cancer cells, 
because  CSCs  are  considered  resistant  to  standard 
chemotherapies, whereas these cells appear to be se-
lectively targeted by curcumin. This targeting would 
be  either  elimination  or  modification  of  the  CSCs. 
Treatments employing curcumin or curcumin deriva-
tives could be particularly effective supplements for 
conventional cancer treatments if they eliminate, dif-
ferentiate, or weaken CSCs. 
In support of this argument, a cell subpopulation 
with stem cell properties in the C6 rat glioma cell line 
is selectively eliminated by curcumin treatment (25), 
and curcumin encapsulated in nanoparticles may be 
effective at inhibiting stem cells implicated in brain 
tumor growth (50). Evidence also indicates that cur-
cumin promotes brain neurogenesis from stem cells 
by  inhibiting  histone  acetylation,  further  promoting 
its use against gliomas (27) and possibly lung cancer. 
Cancer stem cell characteristics are diminished in a 
breast cancer cell line given curcumin (26). Further-
more,  colon  cancer  cells  isolated  according  to  the 
stem-cell  marker  aldehyde  dehydrogenase  are  sup-
pressed by a cucumin analog (63). Colon cancer stem 
cells appear to be effectively killed by treatments of 
curcumin  combined  with  conventional  chemothera-
peutic agents such as 5-fluorouracil or cisplatin (28, 
49).  Journal of Cancer 2012, 3 
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Although  curcumin  has  cancer  prevention  po-
tential and therapeutic value, its poor absorption and 
high rate of degradation could limit clinical applica-
tions (51, 64). Therefore, we conducted the light ex-
periment to evaluate how to enhance the effectiveness 
of curcumin. The results showed that visible light and 
curcumin reduced the LLC cell population by about 
half at a concentration as low as 20 µM, which is con-
sistent  with  previous  findings  (34),  although  those 
studies  found  significant  effects  at  lower  curcumin 
concentrations than we did. Because the reduction in 
LLC cells was smaller when phenol red was not pre-
sent, we suggest that some of the phototoxicity was 
caused by light interacting with this dye rather than 
just  with  curcumin  or  from  an  additional  effect  of 
phenol red. Phenol red has been described as estro-
genic in some cell lines  (65). How this effect might 
produce greater phototoxicity in LLC cells is unclear.  
Nevertheless, our results suggest that the pho-
totoxicity  from  curcumin  in  other  cancer  cell  lines 
may also be due in part to light interacting with phe-
nol red. We also detected cell loss in response to light 
in phenol red-free medium without curcumin present, 
and this effect was smaller in the complete medium, 
suggesting that some of the effective wavelengths of 
light  were  absorbed  by  the  complete  medium.  Be-
cause  of  this  cell  death  caused  by  light  alone,  sub-
stantially  more  intense  light  treatments  were  not 
tested.  The  light  intensity  used  here  was  roughly 
comparable to the intensity of sunlight on an overcast 
day. 
The outcome of photodynamic therapy has been 
positive for some types of lung cancer (66). Our re-
sults suggest that curcumin delivered directly to tu-
mors or through the circulation could be made more 
effective when combined with existing photodynamic 
equipment capable of producing suitable light in the 
visible spectrum. According to curcumin’s peak ab-
sorption in the blue range this wavelength would be 
expected to be most effective. Curcumin is degraded 
in the intestinal lumen before absorption, in the liver, 
and elsewhere (67). A curcumin treatment used along 
with some form of light therapy might offset losses of 
curcumin in the body by making lower doses more 
biologically active. 
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